# GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)

> **NCT00866658** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 311 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Lixisenatide (AVE0010)
- **DRUG:** Placebo
- **DEVICE:** Pen auto-injector
- **DRUG:** Sulfonylurea
- **DRUG:** Basal Insulin

## Key facts

- **NCT ID:** NCT00866658
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 311 (ACTUAL)
- **Last updated:** 2016-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00866658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00866658, "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00866658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*